摘要
目的探讨早期2型糖尿病肾病应用依帕司他联合前列地尔的疗效。方法选取2021年1—12月期间于赤峰市医院确诊的早期2型糖尿病肾病患者80例作为研究对象,并按照随机数表法均分为两组,每组40例。对照组予以单纯依帕司他用药,观察组则予以依帕司他与前列地尔联用方案,对比分析两组用药疗效、治疗前后血清指标变化与生活质量改善情况。结果观察组的临床有效率为95.00%(38/40),高于对照组的67.5%(27/40),差异有统计学意义(χ^(2)=9.928,P<0.05);两组治疗后的血清各指标均较治疗前有所改善,观察组治疗后的血清指标改善效果较对照组明显,差异有统计学意义(P<0.05);观察组的生活质量评分较对照组明显更好,差异有统计学意义(P<0.05);观察组治疗中的不良反应发生率为5.00%(2/40),与对照组的7.5%(3/40)相较,差异无统计学意义(P>0.05)。结论对早期2型糖尿病肾病患者,应用依帕司他联合前列地尔疗效显著,有效改善患者肾功能水平和血清各指标,提高患者的生活质量并改善治疗预后,减少用药后不良反应发生率,用药安全极高。
Objective To investigate the efficacy of epalrestat combined with alprostadil in early type 2 diabetic nephropathy.Methods Eighty patients with clinically confirmed early type 2 diabetic nephropathy diagnosed by the Chifeng Hospital from January and December 2021 were selected as study subjects.And they were divided into two groups according to the random number table method of 40 cases each.The control group was treated with epalrestat alone,while the observation group was treated with epalrestat in combination with alprostadil.The efficacy,changes in serum indexes and improvement in quality of life before and after treatment were compared and analyzed between the two groups.Results The clinical efficiency of the observation group was 95.00%(38/40),higher than 67.5%(27/40)of the control group,the difference was statistically significant(χ^(2)=9.928,P<0.05).All serum indicators improved in both groups after treatment compared with before treatment,the improvement effect of serum indexes in the observation group after treatment was significantly better than that in the control group,the difference was statistically significant(P<0.05).The quality of life scores in the observation group were significantly better than those in the control group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions in the treatment in the observation group was 5.00%(2/40),compared with 7.5%(3/40)in the control group,the difference was not statistically significant(P>0.05).Conclusion In patients with early type 2 diabetic nephropathy,the efficacy of administering epalrestat combined with prostaglandin was significant,can effectively improve patients'renal function level and serum indicators,improve the quality of life and treatment prognosis of patients,reduces the incidence of adverse reactions after medication,and the drug safety is extremely high.
作者
王亚军
杨磊
WANG Yajun;YANG Lei(Department of Endocrinology,Chifeng Hospital,Chifeng,Inner Mongolia Autonomous Region,024000 China)
出处
《系统医学》
2023年第3期103-106,131,共5页
Systems Medicine
基金
赤峰市内科科技计划项目(2017KY003)。
